Race Oncology (RAC) 2023年年度报告「ASX」.pdf

1、Annual Report 2023At the heart of cancer careASX:RACDIRECTORSMs Mary Harney Non-Executive Chair Dr Peter Smith Executive Director Mr Phillip Lynch Non-Executive DirectorCOMPANY SECRETARYPeter Webse REGISTERED OFFICELevel 36,Gateway,1 Macquarie Place Sydney NSW 2000Ph:+61 2 8051 3043 Website:AUDITORH

2、all Chadwick WA 283 Rokeby Road Subiaco WA 6008SECURITIES EXCHANGE LISTING Race Oncology Limiteds shares are listed on the AustralianSecurities Exchange(ASX Code RAC)SHARE REGISTRYAutomic Registry Services Level 5,126 Phillip Street Sydney NSW 2000Ph:1300 288 664Corporate DirectoryRace Oncology Limi

3、ted ACN 149 318 749 Annual Report 20231ContentsChair Letter 22023 Key Highlights 4Directors Report 6Auditors Independence Declaration 24Consolidated Statement of Profit or Loss and Other Comprehensive Income 25Consolidated Statement ofFinancial Position 26Consolidated Statement ofChanges in Equity 2

4、7Consolidated Statement ofCashFlows 28Notes to the Financial Statements 29Directors Declaration 55Independent Auditors Report 56ASX Additional Information 61These accomplishments,along with other milestones in FY2023,have laid the foundations for success in getting bisantrene into the hands of patie

5、nts andpartners.In reflecting on the past year,it is also important to acknowledge the changes to the Board and senior management team to ensure the Company and our lead asset,bisantrene,is suitably positioned forcommercial success.I wish to extend my sincere thanks to my predecessor as Chair,Dr Joh

6、n Cullity whose commitment to Race was enduring.John retired from the Board post-period,however we are fortunate to retain his support as a major shareholder.My appointment as Chair was part of a planned Board renewal strategy,which also saw us welcome Dr Peter(Pete)Smith,initially as Independent No